Best Peptides for Women

Searches for peptides aimed at women cluster around three goals: body composition, skin quality, and low sexual desire. The compounds sold for each sit at very different points on the evidence ladder, and only one of them was tested and approved specifically for women rather than adapted from a study built around men. This guide ranks the field by what was actually measured in trials, not by which one is marketed hardest to a female audience.

Summary

Body composition: the same approved medicines everyone else uses

Nothing in this section is female-specific. Semaglutide, tirzepatide and liraglutide are approved GLP-1 medicines, and their pivotal trials, STEP-1, SURMOUNT-1 and SCALE, enrolled adult men and women together without publishing a separate result by sex. Retatrutide has posted large phase 3 numbers through Eli Lilly's TRIUMPH programme but is not approved anywhere yet. The best peptides for muscle growth and fat loss guide ranks the full field, including the GH-axis compounds, in more depth. The one point worth flagging here: none of these trials measured muscle versus fat separately by sex, so a claim that any of them work differently in women than in men is not something the cited papers support.

Skin: a category built mostly on female study populations

Skin peptides are the other place demand skews toward women, and the human studies happen to follow that pattern. The randomised, placebo-controlled argireline trial (Wang and colleagues, 2013) enrolled 60 Chinese adults, and the GHK-Cu cosmetic studies summarised in Pickart and Margolina's 2018 review were mostly conducted in women with photoaged facial and thigh skin. That does not make the biology sex-specific, since collagen and elastin turnover work the same way in men, but it does mean the evidence base happens to describe female skin more directly than male skin. The best peptides for skin guide ranks argireline, GHK-Cu and SNAP-8 by evidence in full; GHK-Cu (topical) is the entry point of that ranking most relevant here.

Sexual health: the one place the trial data was built for women

This is where sex matters most to the ranking. PT-141 (bremelanotide) is one of only two compounds in this library approved for an indication that names women specifically. The US FDA approved it in June 2019 as Vyleesi, a 1.75 mg autoinjector, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, based on the two identical RECONNECT phase 3 trials in 1,267 women. The trials found statistically significant increases in desire scores against placebo, alongside a defined side-effect profile: 40% nausea versus 1.3% on placebo, and blood pressure that rises briefly after each dose. PT-141 was also tested in men with erectile dysfunction decades ago, but that work never led to an approval, and the current label explicitly excludes men.

Kisspeptin is the other compound with human data collected specifically in women with low desire. A 2022 randomised, double-blind crossover trial at Imperial College London gave 32 premenopausal women with HSDD a single 75-minute infusion of kisspeptin-54, and it changed brain activity in response to erotic videos compared with placebo. That is a single lab session, not a treatment course, and no trial has measured whether repeated dosing changes desire or activity at home.

Melanotan-2 also raises arousal, as a side effect of the same melanocortin receptors PT-141 was built from, but it was never approved and its dermatology case-report record of new and changing moles is a real safety concern rather than a theoretical one. The full ranking of PT-141, kisspeptin and melanotan-2 against each other is in the best peptides for libido guide.

Safety notes

The GLP-1 medicines share a class boxed warning on thyroid C-cell tumours seen in rodents, and their most common side effects are gastrointestinal; the side effect management guide covers monitoring. PT-141's most common side effects are nausea, flushing and a brief rise in blood pressure after each dose, and focal skin darkening was reported in 1% of women in the phase 3 trials, a point relevant for Filipino skin types. Kisspeptin's human safety data is limited to short, well-tolerated single sessions, so anything beyond that is unknown.

Status in the Philippines

Ozempic, Wegovy, Mounjaro, Victoza and Saxenda are registered prescription medicines here, and prescribing belongs with a licensed Philippine physician. PT-141, kisspeptin and retatrutide are not registered with FDA Philippines and are not controlled substances under RA 9165; where they circulate locally, it is only through research-peptide suppliers, not as approved medicines. GHK-Cu creams and serums are sold as cosmetics, which FDA Philippines regulates separately from medicines, so a bottle on a drugstore shelf carries no clinical claim beyond what its own label states.

Enforcement in 2026 has focused on the GLP-1 medicines specifically: the Philippine College of Physicians issued an advisory in March against compounded and non-registered Ozempic and Mounjaro, and the NBI and FDA Philippines acted against unregistered sellers in Tondo and a Pasig clinic in May. That enforcement pattern is a reason to treat any research-market vial sold as "semaglutide" or "tirzepatide" with the same scrutiny as one sold as PT-141 or kisspeptin: none of it is a substitute for a registered pharmacy product with a batch number a physician can verify.